Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM).

被引：0
|
作者：
Bringhen, Sara
Richardson, Paul G.
Voorhees, Peter Michael
Plesner, Torben
Mellqvist, Ulf-Henrik
Zonder, Jeffrey A.
Reeves, Brandi Nikcole
Zavisic, Stojan
Harmenberg, Johan
Obermueller, Jakob
Sonneveld, Pieter
机构：
[1] Univ Torino, Div Hematol, Turin, Italy
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Carolinas Hlth Care Syst, Levine Canc Inst, Charlotte, NC USA
[4] Vejle Hosp, Dept Hematol, Vejle, Denmark
[5] Boras Hosp, Boras, Sweden
[6] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[7] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[8] Oncopeptides AB, Stockholm, Sweden
[9] Erasmus MC, Rotterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8043
引用
收藏
页数：2
相关论文
共 50 条
  • [1] HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Blade, Joan
    Cavo, Michele
    Rodriguez Otero, Paula
    Leleu, Xavier
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Alegre, Adrian
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Harmenberg, Johan
    Zavisic, Stojan
    Thuresson, Sara
    Ohman, Oskar
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] FINAL PHASE 2 STUDY DATA OF MELFLUFEN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)
    Palumbo, A.
    Magarotto, V.
    Sonneveld, P.
    Plesner, T.
    Paba-Prada, C.
    Voorhees, P.
    Mellqvist, U. H.
    Byrne, C.
    Harmenberg, J.
    Nordstrom, E.
    Zubair, H.
    Richardson, P. G.
    HAEMATOLOGICA, 2016, 101 : 85 - 85
  • [3] HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations
    Nadeem, Omar
    Richardson, Paul G.
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Creixenti, Joan Blade
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Norkin, Maxim
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Amor, Adrian Alegre
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Sandberg, Anna
    Pelaez, Ivonne
    Jaques, Christian
    Orre, Marie
    Cavo, Michele
    BLOOD, 2020, 136
  • [4] Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104)
    Pour, Ludek
    Efebera, Yvonne
    Granell, Miquel
    Hajek, Roman
    Oriol, Albert
    Delaunay, Jacques
    Le Du, Katell
    Eveillard, Jean-Richard
    Karlin, Lionel
    Maisnar, Vladimir
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Moreb, Jan
    Ribrag, Vincent
    Richardson, Paul G.
    Straub, Jan
    Byrne, Catriona
    Jacques, Christian
    Zubair, Hanan
    Ocio, Enrique
    CANCER RESEARCH, 2019, 79 (13)
  • [5] Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Rodriguez Otero, Paula
    Moreb, Jan
    Blade, Joan
    Hassoun, Hani
    Cavo, Michele
    Alegre, Adrian
    Mazumder, Amitabha
    Maisel, Christopher
    Paner, Agne
    Leleu, Xavier
    Zonder, Jeffrey A.
    Harmenberg, Johan
    Thuresson, Sara
    Zubair, Hanan
    Mateos, Maria-Victoria
    CANCER RESEARCH, 2019, 79 (13)
  • [6] Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma
    Hossain, Shahrier
    Mo, Clifton
    Patches, Sarah
    Leblebjian, Houry
    Goodrich, Kathryn
    Regan, Eileen
    O'Neill, Kathleen
    Noonan, Kim
    Richardson, Paul G.
    Laubach, Jacob
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025,
  • [7] HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis
    Richardson, Paul G.
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Amor, Adrian Alegre
    Paner, Agne
    Maisel, Christopher
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Zamagni, Elena
    Thuresson, Marcus
    Harmenberg, Johan
    Harlin, Olof
    Creixenti, Joan Blade
    BLOOD, 2020, 136
  • [8] HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE (DEX) IN 55 PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH EXTRAMEDULLARY DISEASE (EMD)-SUBGROUP ANALYSIS
    Zamagni, E.
    Richardson, P. G.
    Mateos, M. V.
    Oriol, A.
    Larocca, A.
    Cavo, M.
    Rodriguez-Otero, P.
    Leleu, X.
    Norkin, M.
    Nadeem, O.
    Hiemenz, J. W.
    Hassoun, H.
    Touzeau, C.
    Alegre, A.
    Paner, A.
    Maisel, C.
    Mazumder, A.
    Raptis, A.
    Puig, N.
    Thuresson, M.
    Harmenberg, J.
    Harlin, O.
    Blade, J.
    HAEMATOLOGICA, 2021, 106 (10) : 14 - 14
  • [9] Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Blade, Joan
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Alegre, Adrian
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Moreb, Jan S.
    Anderson, Kenneth C.
    Laubach, Jacob P.
    Thuresson, Sara
    Thuresson, Marcus
    Byrne, Catriona
    Harmenberg, Johan
    Bakker, Nicolaas A.
    Mateos, Maria-Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (07) : 757 - +
  • [10] HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis
    Oriol, Albert
    Richardson, Paul G.
    Mateos, Maria-Victoria
    Larocca, Alessandra
    Creixenti, Joan Blade
    Cavo, Michele
    Rodriguez-Otero, Paula
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Amor, Adrian Alegre
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Strang, Peter
    Sandberg, Anna
    Jaques, Christian
    Thuresson, Marcus
    Orre, Marie
    Leleu, Xavier
    BLOOD, 2020, 136
12345